CL2021002866A1 - Tratamiento de la cefalea usando anticuerpos anti-cgrp. - Google Patents

Tratamiento de la cefalea usando anticuerpos anti-cgrp.

Info

Publication number
CL2021002866A1
CL2021002866A1 CL2021002866A CL2021002866A CL2021002866A1 CL 2021002866 A1 CL2021002866 A1 CL 2021002866A1 CL 2021002866 A CL2021002866 A CL 2021002866A CL 2021002866 A CL2021002866 A CL 2021002866A CL 2021002866 A1 CL2021002866 A1 CL 2021002866A1
Authority
CL
Chile
Prior art keywords
cgrp antibodies
headache treatment
headache
treatment
cgrp
Prior art date
Application number
CL2021002866A
Other languages
English (en)
Spanish (es)
Inventor
Roger K Cady
Joseph Hirman
Barbara Schaeffler
Lahar Mehta
Jeffrey T L Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2021002866A1 publication Critical patent/CL2021002866A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2021002866A 2019-05-02 2021-10-29 Tratamiento de la cefalea usando anticuerpos anti-cgrp. CL2021002866A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
CL2021002866A1 true CL2021002866A1 (es) 2022-06-17

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002866A CL2021002866A1 (es) 2019-05-02 2021-10-29 Tratamiento de la cefalea usando anticuerpos anti-cgrp.

Country Status (20)

Country Link
US (1) US20220251178A1 (https=)
EP (1) EP3962522A4 (https=)
JP (2) JP2022533030A (https=)
KR (1) KR20220004053A (https=)
CN (1) CN113811326A (https=)
AU (1) AU2020267107B2 (https=)
BR (1) BR112020027063A2 (https=)
CA (1) CA3133571A1 (https=)
CL (1) CL2021002866A1 (https=)
DO (1) DOP2021000215A (https=)
EA (1) EA202192865A1 (https=)
GE (2) GEP20257803B (https=)
IL (1) IL287759A (https=)
JO (1) JOP20210247A1 (https=)
MA (1) MA55815A (https=)
MX (1) MX2021013426A (https=)
PH (1) PH12021552422A1 (https=)
SG (1) SG11202110637RA (https=)
WO (1) WO2020222892A1 (https=)
ZA (1) ZA202106627B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
MA55815A (fr) 2022-03-09
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
GEP20257803B (en) 2025-10-10
EA202192865A1 (ru) 2022-02-14
PH12021552422A1 (en) 2022-07-11
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09
DOP2021000215A (es) 2021-11-21

Similar Documents

Publication Publication Date Title
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
NI202100063A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
ECSP21052194A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
ECSP20063690A (es) Anticuerpos
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
EA202190504A1 (ru) Способы лечения псориаза
AR117579A1 (es) Anticuerpos específicos para gucy2c y sus usos